What Did the New Study Find?
This new study from researchers at the Mayo Clinic underscores how menopausal hormone therapy (MHT) may enhance the effectiveness of treatments like tirzepatide when used together by postmenopausal women with obesity, says Dr. Bronwyn Holmes, a physician specializing in hormone optimization and cellular health, who also serves as a member of the medical advisory board at Eden. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to treat type 2 diabetes.
Women in the study using tirzepatide plus MHT saw a 17% reduction in total body weight loss, compared to those using tirzepatide alone, who saw a 14% reduction. Additionally, a higher percentage of MHT users (45%) also achieved at least 20% total body weight loss, compared to those who didn’t use MHT, who saw an 18% total body weight loss.
